マフェニド
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/02/13 18:46:42」(JST)
[Wiki en表示]
Mafenide
|
|
Systematic (IUPAC) name |
4-(Aminomethyl)benzenesulfonamide
|
Clinical data |
Trade names |
Sulfamylon |
AHFS/Drugs.com |
monograph |
Legal status |
|
Routes of
administration |
Topical |
Identifiers |
CAS Number |
138-39-6 N |
ATC code |
D06BA03 |
PubChem |
CID 3998 |
ChemSpider |
3858 Y |
UNII |
58447S8P4L Y |
KEGG |
D02351 Y |
ChEMBL |
CHEMBL419 Y |
Chemical data |
Formula |
C7H10N2O2S |
Molar mass |
186.233 g/mol |
|
InChI
-
InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11) Y
-
Key:TYMRLRRVMHJFTF-UHFFFAOYSA-N Y
|
NY (what is this?) (verify) |
Mafenide (INN; usually as mafenide acetate, trade name Sulfamylon) is a sulfonamide-type medication used as an antibiotic. It was approved by the FDA in 1948.
Contents
- 1 Uses
- 2 Mechanism of action
- 3 Adverse reactions
- 4 Drug interactions
- 5 Contraindications
- 6 Dosage
- 7 References
- 8 External links
Uses
Mafenide is used to treat severe burns.[1][2] It is used topically as an adjunctive therapy for second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns.[3]
Mechanism of action
Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns.
Adverse reactions
|
This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2014) |
Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis.
Drug interactions
There are no significant interactions.
Contraindications
Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.
Dosage
For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.
References
- ^ Siuda J. F., Cihonski C. D. (1972). "New compounds: carbamate derivatives of mafenide (homosulfanilamide)". J. Pharm. Sci. 61 (11): 1856–1857. doi:10.1002/jps.2600611143. PMID 4652670.
- ^ Haynes B. (1971). "Mafenide acetate in Burn Treatment". New England J. Medic. 284 (23): 1324. doi:10.1056/NEJM197106102842310. PMID 5576444.
- ^ Haik J, Ashkenazy O, Sinai S, et al. (November 2005). "Burn care standards in Israel: lack of consensus". Burns 31 (7): 845–9. doi:10.1016/j.burns.2005.04.012. PMID 15967581.
External links
- Mafenide information on RxList
Antibiotics and chemotherapeutics for dermatological use (D06)
|
|
Antibiotics |
Tetracycline and derivatives
|
- Demeclocycline
- Chlortetracycline
- Oxytetracycline
- Tetracycline
|
|
Others
|
- Amphenicol: Chloramphenicol
- Aminoglycosides: Neomycin
- Gentamicin
- Amikacin
- Streptogramin: Virginiamycin
- other: Fusidic acid
- Bacitracin
- Tyrothricin
- Mupirocin
|
|
|
Chemotherapeutics |
Sulfonamides
|
- Silver sulfadiazine
- Sulfathiazole
- Mafenide
- Sulfamethizole
- Sulfanilamide
- Sulfamerazine
|
|
Antivirals
|
- Aciclovir
- Penciclovir
- Idoxuridine
- Edoxudine
- Imiquimod
- Resiquimod
- Podophyllotoxin
- Docosanol
- Tromantadine
- Inosine
- Lysozyme
- Ibacitabine
- Lysine
|
|
Other
|
- Ingenol mebutate
- Metronidazole
|
|
|
Antibacterials: nucleic acid inhibitors (J01E, J01M)
|
|
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis) |
DHFR inhibitor |
- 2,4-Diaminopyrimidine
- Trimethoprim#
- Brodimoprim
- Tetroxoprim
- Iclaprim†
|
|
Sulfonamides
(DHPS inhibitor) |
Short-
acting |
- Sulfaisodimidine
- Sulfamethizole
- Sulfadimidine
- Sulfapyridine
- Sulfafurazole
- Sulfanilamide
- Sulfathiazole
- Sulfathiourea
|
|
Intermediate-
acting |
- Sulfamethoxazole
- Sulfadiazine#
- Sulfamoxole
|
|
Long-
acting |
- Sulfadimethoxine
- Sulfadoxine
- Sulfalene
- Sulfametomidine
- Sulfametoxydiazine
- Sulfamethoxypyridazine
- Sulfaperin
- Sulfamerazine
- Sulfaphenazole
- Sulfamazone
|
|
Other/ungrouped |
- Sulfacetamide
- Sulfadicramide
- Sulfametrole
|
|
|
Combinations |
- Trimethoprim/sulfamethoxazole#
|
|
|
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication) |
1st g. |
- Cinoxacin‡
- Flumequine‡
- Nalidixic acid‡
- Oxolinic acid‡
- Pipemidic acid‡
- Piromidic acid‡
- Rosoxacin‡
|
|
Fluoro-
quinolones |
2nd g. |
- Ciprofloxacin#
- Ofloxacin
- Enoxacin‡
- Fleroxacin‡
- Lomefloxacin‡
- Nadifloxacin‡
- Norfloxacin‡
- Pefloxacin‡
- Rufloxacin‡
|
|
3rd g. |
- Levofloxacin
- Balofloxacin‡
- Grepafloxacin‡
- Pazufloxacin‡
- Sparfloxacin‡
- Temafloxacin‡
- Tosufloxacin‡
|
|
4th g. |
- Besifloxacin
- Gatifloxacin
- Finafloxacin
- Gemifloxacin
- Moxifloxacin
- Clinafloxacin†
- Garenoxacin‡
- Prulifloxacin‡
- Sitafloxacin‡
- Trovafloxacin‡/Alatrofloxacin‡
|
|
Vet. |
- Danofloxacin
- Difloxacin
- Enrofloxacin
- Ibafloxacin
- Marbofloxacin
- Orbifloxacin
- Pradofloxacin
- Sarafloxacin
|
|
|
Newer non-fluorinated |
|
|
Related (DG) |
- Aminocoumarins: Novobiocin
|
|
|
Anaerobic DNA
inhibitors |
Nitro- imidazole derivatives |
- Metronidazole#
- Tinidazole
- Ornidazole
|
|
Nitrofuran derivatives |
- Nitrofurantoin#
- Furazolidone‡
- Nifurtoinol
|
|
|
RNA synthesis |
Rifamycins/
RNA polymerase |
- Rifampicin#
- Rifabutin
- Rifapentine
- Rifaximin
- Rifalazil§
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- The Effect of Antiseptics on Adipose-Derived Stem Cells.
- Kim BS1, Ott V, Boecker AH, Stromps JP, Paul NE, Alharbi Z, Cakmak E, Bernhagen J, Bucala R, Pallua N.
- Plastic and reconstructive surgery.Plast Reconstr Surg.2017 Mar;139(3):625-637. doi: 10.1097/PRS.0000000000003125.
- PMID 28234837
- 2.5% Mafenide Acetate: A Cost-Effective Alternative to the 5% Solution for Burn Wounds.
- Afshari A1, Nguyen L, Kahn SA, Summitt B.
- Journal of burn care & research : official publication of the American Burn Association.J Burn Care Res.2017 Jan/Feb;38(1):e42-e47. doi: 10.1097/BCR.0000000000000425.
- PMID 27606553
- Hydrofiber Dressing Saturated With Mafenide Acetate Extends the Duration of Antimicrobial Activity.
- Kahn SA1, Afshari A, Nguyen L, Shinha T, Huff T, Montgomery AC, Stratton C, Summitt B.
- Journal of burn care & research : official publication of the American Burn Association.J Burn Care Res.2016 Oct 13. [Epub ahead of print]
- PMID 27775984
Japanese Journal
- The efficacy of 5% sulfamylon solution for the treatment of contaminated explanted human meshed skin grafts
- 熱傷受傷時における肺変化に関する病理学的研究:(II) 実験的熱傷時における肺変化に関する超微形態学的研究
- 久野 佑三
- 日本医科大学雑誌 46(1), 45-50_6, 1979
- A remarkable progress in clinical therapeutic aspects on the thermal burns has been made recently. Preventions of the infections and subsequent septic shock with Gramnegative bacilli have been achieve …
- NAID 130003917825
- 熱傷受傷時における肺変化に関する病理学的研究:(I) 人体病理学的研究
- 久野 佑三
- 日本医科大学雑誌 46(1), 40-44_5, 1979
- … Above all, one of the most remarkable change is a decrease of the burn wound sepsis due to the improvement of topical applications of sulfamylon cream and silver sulfadiazine, and an increase of the pulmonary complications, such as pneumonia, pleuritis, pulmonary edema etc.. …
- NAID 130003917824
Related Pictures
★リンクテーブル★
[★]
- 英
- mafenide
- 化
- 酢酸マフェニド mafenide acetate
- 同
- マフェナイド
- 商
- Sulfamylon